PatrĂ­cia Silva, PhD,  director of science content—

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

CFFT Awards Genzyme $14 Million Research Grant

The nonprofit affiliate of the Cystic Fibrosis Foundation (CFF), Cystic Fibrosis Foundation Therapeutics, Inc., will expand its research partnership with Genzyme in a collaboration that will be supported by $14 million in additional funding. The funding is expected to be invested in developing novel therapy options for patients…

MCLife Launches #CFShoeSelfie Campaign for Cystic Fibrosis

The residential apartment brand MCLife, which belongs to MC Companies, is launching the #CFShoeSelfie campaign, with the main purpose of raising awareness about the chronic disease cystic fibrosis (CF). At a time when emails, social media, television, and advertisements bombard everyone with images that are easily forgotten, the company aims…

European Commission Authorizes PARI’s Vantobra for CF Patients

Pharmaceutical company PARI Pharma received marketing authorization from the European Commission for its nebulizer Vantobra, a breakthrough therapy for patients who suffer from cystic fibrosis (CF). The product is a novel and highly concentrated tobramycin therapeutic option for inhalation that uses a Tolero nebulizer, and will now be commercialized in…

Travel Lake Anna Invests All Profits to Find CF Cure

Travel Lake Anna might look like a typical travel agency dedicated to promoting vacations around Lake Anna, a state park located in Virginia. However, the company has a unique business model and purpose. Husband and wife team Chris and Laura Denkers created and manage the company in support of their two sons who were…

Aridis Names New Chief Medical Officer To Lead Development of CF Treatment of Pseudomonas Aeruginosa

Biopharmaceutical company Aridis Pharmaceuticals, Inc. has named Paul-Andre de Lame, MD as its new chief medical officer to help the company in their efforts to develop new anti-infective and immune therapies to treat infectious diseases. Aridis is currently developing a reactive monoclonal antibody drug called Aerucin, to treat Pseudomonas aeruginosa associated with cystic fibrosis.

Crystal Climbs for CF: Hiking Against the Odds

As a chronic disease that causes difficulties in breathing, persistent coughing, thick mucus and wheezing, most patients with cystic fibrosis (CF) struggle to manage the symptoms, often making exercise extremely difficult. 23 year-old Crystal Park, however, decided to take control of her body and the disease and, despite the difficulties,…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.